BioTuesdays

Tag - Jason Kolbert

Can-Fite

Dawson James ups Can-Fite to buy on valuation call

Dawson James upgraded Can-Fite BioPharma (NYSE American, TASE:CANF) to “buy” from “neutral” with a $6 price target. The stock closed at $1.74 on April 28. Analyst Jason Kolbert writes that the stock is reaching new lows...

NRx-Pharma-Logo

Dawson James ups NRx Pharma PT to $9 from $3

Dawson James Securities raised its price target for NRx Pharmaceuticals (NASDAQ:NRXP) to $9 from $3, saying the company’s NRX-101 drug candidate could change the treatment paradigm for depression, PTSD, and related...

NRx-Pharma-Logo

Dawson James starts NRx Pharma at buy; PT $3.00

Dawson James Securities initiated coverage of NRx Pharmaceuticals (NASDAQ:NRXP) with a “buy” rating and $3.00 price target. The stock closed at 68 cents on March 16. NRx Pharmaceuticals is a clinical-stage...

Dawson James starts Hillstream at buy; PT $4

Dawson James Securities initiated coverage of Hillstream BioPharma (NASDAQ:HILS) with a “buy” rating and price target of $4. The stock closed at $1.24 on Feb. 21. Hillstream is a preclinical biotechnology company...

Dawson James starts Genprex at buy; PT $3

Dawson James Securities initiated coverage of Genprex (NASDAQ:GNPX) with a “buy” rating and $3 price target. The stock closed at $1.34 on Jan. 27. Genprex is a clinical-stage gene therapy company pioneering the...

Zomedica Pharmaceuticals

Dawson James starts Zomedica at buy; PT $6

Dawson James initiated coverage of Zomedica (NYSEA:ZOM) with a “buy” rating and price target of $6. The stock closed at 20 cents on Jan. 5. Analyst Jason Kolbert writes that Zomedica is positioning itself as a leading...

Smart for Life Logo

Dawson James starts Smart for Life at buy; PT $8

Dawson James initiated coverage of Smart for Life (NASDAQ:SMFL) with a “buy” rating and $8 price target. The stock closed at 53 cents on Aug. 26. The company’s goal is the development, marketing, manufacturing...